Alps Advisors Inc Alx Oncology Holdings Inc Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.19 - $7.35 $1,328 - $2,329	317 Added 1.06%	30,358 $145,000
Q2 2023 Aug 14, 2023	BUY	$4.37 - $9.56 $13,944 - $30,505	3,191 Added 11.88%	30,041 $225,000
Q1 2023 May 10, 2023	SELL	$4.52 - $11.71 $3,855 - $9,988	-853 Reduced 3.08%	26,850 $121,000
Q4 2022 Feb 14, 2023	BUY	$9.51 - $12.95 $51,819 - $70,564	5,449 Added 24.49%	27,703 $312,000
Q3 2022 Nov 14, 2022	SELL	$8.23 - $15.14 $15,439 - $28,402	-1,876 Reduced 7.77%	22,254 $213,000
Q2 2022 Aug 11, 2022	SELL	$5.89 - $19.46 $103,864 - $343,157	-17,634 Reduced 42.22%	24,130 $195,000
Q1 2022 May 16, 2022	SELL	$13.65 - $22.06 $69,724 - $112,682	-5,108 Reduced 10.9%	41,764 $706,000
Q4 2021 Feb 09, 2022	SELL	$21.49 - $74.4 $55,358 - $191,654	-2,576 Reduced 5.21%	46,872 $1.01 Million
Q3 2021 Nov 15, 2021	SELL	$52.51 - $80.91 $169,817 - $261,662	-3,234 Reduced 6.14%	49,448 $3.65 Million
Q2 2021 Aug 11, 2021	BUY	$52.2 - $75.23 $2.75 Million - $3.96 Million	52,682 New	52,682 $2.88 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $74.6M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.